James Utterback has been named CEO of M2Gen, a wholly owned for-profit subsidiary of Moffitt Cancer Center, effective Dec. 7. Utterback will be responsible for developing and implementing effective growth strategies, determining commercialization opportunities, and establishing and executing pharmaceutical company-funded clinical trials.
Trending:
TAMPA: Utterback named CEO at Moffitt's M2Gen subsidiary